Pages
Home
Investments
Transaction Advisory
Investment Research and Business Due Diligence
Contact Us
Friday, January 1, 2016
AstraZeneca is nearing another Patent Cliff
Over the next three years AZN will need to replace sales worth $10b with new pipeline products. In 2015, AZN is expected to generate $24b in annual sales. The sales at risk of generic competition is approximately 40 percent of its 2015 sales
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)